Adakveo (crizanlizumab-tmca) from Novartis is FDA indicated for reducing the number of vaso-occlusive crises in people aged 16 years and older with sickle cell disease.
Novartis describes it as “the first and only once-monthly medication to reduce the number of pain crises in sickle cell disease.”
The drug works by inhibiting selectin, a group of carbohydrate-binding transmembrane molecules associated with cells clinging together, which results in vaso-occlusive crisis
Filed Under: Hematology
Tell Us What You Think!
You must be logged in to post a comment.